Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents

Clinical Cancer Research

Volumn 5, Issue 6, 1999, Pages 1569-1582

  Sudbeck, Elise A ^b   Liu, Xing Ping ^b   Narla, Rama Krishna ^a,b   Mahajan, Sandeep ^b   Ghosh, Sutapa ^b   Mao, Chen ^b   Uckun, Fatih M ^a,b  

^a Parker Hughes Cancer Center   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (2' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; 4 (2',5' DIBROMOPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; 4 (3' BROMO 4' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; 4 (3' BROMO 4' METHYLPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; 4 (3' BROMOPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; 4 (3',5' DIBROMO 4' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; 4 (4 HYDROXYANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 (4' HYDROXYPHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; 4 (PHENYL)AMINO 6,7 DIMETHOXYQUINAZOLINE; ANTILEUKEMIC AGENT; DNA BINDING PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; WHI P 111; WHI P 112; WHI P 132; WHI P 154; WHI P 258; WHI P 79; WHI P 97;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CELL DEATH; CONTROLLED STUDY; DRUG DESIGN; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; COMPUTER SIMULATION; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; LEUKEMIA; MODELS, MOLECULAR; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; QUINAZOLINES; SUBSTRATE SPECIFICITY; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 0033053383     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ihle, J. N. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv. Immunol., 60: 1-35, 1995.
2. Witthuhn, B. A., Williams, M. D., Kerawalla, H., and Uckun, F. M. Differential substrate recognition capabilities of Janus family protein lyrosine kinases within the interleukin 2 receptor (I12R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery. Leuk. Lymphoma, 32: 289-297, 1999.
3. Horvath, C. M., and Darnell, J. E. The state of the STATs: recent developments in the study of signal transduction to the nucleus. Curr. Opin. Cell. Biol., 9: 233-239, 1997.
4. Levy, D. E. The house that Jak/STAT built. Cytokine Growth Factor Rev., 8: 81-90, 1997.
5. Demoulin, J. B., Uyttenhove, C., Van Roost, E., DeLestre, B., Donckers, D., Van Snick, J., and Renauld, J. C. A single tyrosine of the interleukin-9 (IL-9) receptor is required for STAT activation, antiapoptotic activity, and growth regulation by IL-9. Mol. Cell. Biol., 16: 4710-4716, 1996.
6. Jurlander, J., Lai, C. F., Tan, J., Chou, C. C. Geisler, C. H., Schriber, J., Blumenson, L. E., Narula, S. K., Baumann, H., and Caligiuri, M. A. Characterization of interleukin-10 receptor expression on B-cell chronic lymphocytic leukemia cells. Blood, 89: 4146-4152, 1997.
7. Kaneko, S., Suzuki, N., Koizumi, H., S. Yamamoto, S., and Sakane, T. Rescue by cytokines of apoptotic cell death induced by IL-2 deprivation of human antigen-specific T cell clones. Clin. Exp. Immunol., 109: 185-193, 1997.
8. Nakamura, N., Chin, H., Miyasaka, N., and Miura, O. An epidermal growth factor receptor/Jak2 tyrosine kinase domain chimera induces tyrosine phosphorylation of Stat5 and transduces a growth signal in hematopoietic cells. J. Biol. Chem., 271: 19483-19488, 1996.
9. Sicheri, F., Moarefi, I., and Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature (Lond.), 385: 602-609, 1997.
10. Mohammadi, M., Schlessinger, J., and Hubbard, S. R. Structure of the FGF receptor tyrosine kinase domain reveals a novel autoinhibitory mechanism. Cell, 86: 577-587, 1996.
11. Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., and Schlessinger, J. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science (Washington DC), 276: 955-960, 1997.
12. Hubbard, S. R., Wei, L., Ellis, L., and Hendrickson, W. A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature (Lond.), 372: 746-754, 1994.
13. Sack, J. S. CHAIN: a crystallographic modeling program. J. Mol. Graphics, 6: 244-245, 1988.
14. Brünger, A. T. X-PLOR, A System for X-Ray Crystallography and NMR, Ed. 3.1. New Haven, CT: Yale University Press, 1992.
15. Ghosh, S., Zheng, Y., Jun, X., Narla, R., Mahajan, S., Navara, C., Mao, C., Sudbeck, E. A., and Uckun, F. M. α-Cyano-β-hydroxy-β-methyl-N-[4-(trifluoromethoxy)phenyl] propenamide: an inhibitor of the EGF receptor tyrosine kinase with potent cytotoxic activity against breast cancer cells. Clin. Cancer Res., 4: 2657-2668, 1998.
16. Mahajan, S., Ghosh, S., Sudbeck, E. A., Zheng, Y., Downs, S., Hupke, M., and Uckun, F. M. Rational design and synthesis of a novel antileukemic agent targeting Bruton's tyrosine kinase (BTK): LFM-A13 [α-cyano-β-hydroxy-β-methyl-N-(2,5-dibromophenyl)propenamide]. J. Biol. Chem., 274: 9587-9599, 1999.
17. Bohm, H. J. The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure. J. Comput. Aided Mol. Des., 8: 243-256, 1994.
18. Rewcastle, G. W., Denny, W. A., Bridges, A. J., Zhou, H., Cody, D. R., McMichael, A., and Fry, D. W. Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl) amino]- and 4-(phenylamino)quinazolines as potent adenosine 5′-triphosphate binding site inhibitors of the tyrosinekinase domain of the epidermal growth factor receptor. J. Med. Chem., 38: 3482-3487, 1995.
19. Vassilev, A., Ozer, Z., Navara, C., Mahajan, S., and Uckun, F. M. Bruton's tyrosine kianse (BTK) as an inhibitor of the Fas/CD95 death inducing signaling complex (DISC). J. Biol. Chem., 274: 1646-1656, 1999.
20. Uckun, F. M., Waddick, K. G., Mahajan, S., Jun, X., Takata, M., Bolen, J., and Kurosaki, T. Bruton's tyrosine kinase as a mediator of radiation-induced apoptosis in B-lineage lymphoid cells. Science (Washington DC), 22: 1096-1100, 1996.
21. Goodman, P. A., Niehoff, L. B., and Uckun, F. M. Role of tyrosine kinases in induction of the c-jun proto-oncogene in irradiated B-lineage lymphoid cells. J. Biol. Chem., 273: 17742-17748, 1998.
22. Mahajan, S., Fargnoli, J., Burkhardt, A. L., Kut, S. A., Saouaf, S. J., and Bolen, J. B. Src family protein tyrosine kinases induce autoactivation of Bruton's tyrosine kinase. Mol. Cell. Biol., 15: 5304-5311, 1995.
23. Uckun, F. M., Evans, W. E., Forsyth, C. J., Waddick, K. G., Ahlgren, L. T., Chelstrom, L. M., Burkhardt, A., Bolen, J., and Myers, D. E. Biotherapy of B-cell precursor leukemia by targeting genistein to CD19-associated tyrosine kinases. Science (Washington DC), 267: 886-891, 1995.
24. Uckun, F. M., Tuel-Ahlgren, L., Waddick, K. G., Jun, X., Jin, J., Myers, D. E., Rowley, R. B., Burkhardt, A. L., and Bolen, J. B. Physical and functional interactions between Lyn and p34CDC2 kinases in irradiated human B-cell precursors. J. Biol. Chem., 271: 6396-6397, 1996.
25. Uckun, F. M., Jun, X., Narla, R. K., Zeren, T., Venkatachalam, T., Waddick, K., Rostostev, A., and Myers, D. E. Cytotoxic activity of EGF-genistein against human breast cancer cells. Clin. Cancer Res., 4: 901-912, 1998.
26. Fujii, H., Cody, S. H., Seydel, U., Papadimitriou, J. M., Wood, D. J., and Zheng, M. H. Recording of mitochondrial transmembrane potential and volume in cultured rat osteoclasts by confocal laser scanning microscopy. Histochem J., 29: 571-581, 1997.
27. Mancini, M., Anderson, B. O., Caldwell, E., Sedghinasab, M., Paty, P. B., and Hockenbery, D. M. Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J. Cell Biol., 138: 449-469, 1997.
28. Petit, P. X., Lecoeur, H., Zorn, E., Dauguet, C., Mignotte, B., and Gougeon, M. L. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J. Cell Biol., 130: 157-167, 1995.
29. Smiley, S. T., Reers, M., Mottola-Hartson, C., Lin. M., Chen, A., Smith, T. W., Steele, G. D., and Chen, L. Intracellular heterogeneity in mitochondrial membrane potentials revealed by J-aggregate-forming lipophilic cation JC-1. Proc. Natl. Acad. Sci. USA, 88: 3671-3675, 1991.
30. Maftah, A., Petit, J. M., Ratinaud, M. H., and Julien, R. 10-N nonyl acridine orange: a fluorescent probe which stains mitochondria independently of their energetic state. Biochem. Biophys. Res. Commun., 164: 185-190, 1989.
31. Narla, R. K., Liu, X-P., Myers, D. E., and Uckun, F. M. 4-(3′-Bromo-4′ hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. Clin. Cancer Res., 4: 1405-1414, 1998.
32. Zhu, D-M., Narla, R. K., Fang, W-H., Chia, N-C., and Uckun, F. M. Calphostin C triggers calcium-dependent apoptosis in human acute lymphoblastic leukemia cells. Clin. Cancer Res., 4: 2967-2976, 1998.
33. D'Cruz, O., P., G., and Uckun, F. M. Spermicidal activity of metallocene complexes containing vanadium (IV)1 in humans. Biol. Reprod., 58: 1515-1526, 1998.
34. Uckun, F. M., Kazimiera, J. G-P., Kersey, J. H., Houston, L., and Vallera, D. A. Use of a novel colony assay to evaluate the cytotoxicity of an immunotoxin containing pokeweed antiviral protein against blast progenitor cells freshly obtained from patients with common B-lineage acute lymphoblastic leukemia. J. Exp. Med., 163: 347-368, 1986.
35. Messinger, Y., Yanishevski, Y., Ek, O., Zeren, T., Waurzyniak, B., Gunther, R., Chelstrom, L., Chandan-Langlie, M., Schneider, E., Myers, D. E., Evans, W., and Uckun, F. M. In vivo toxicity and pharmacokinetic features of B43 (anti-CD19)-genistein immunoconjugate in nonhuman primates. Clin. Cancer Res., 4: 165-170, 1998.
36. Hubbard, S. R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J., 16: 5572-5581, 1997.
37. Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., Levitzki, A., and Roifman, C. M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (Lond.), 379: 645-648, 1996.
38. Kristupaitis, D., Dibirdik, I., Vassilev, A., Mahajan, S., Kurosaki, T., Chu, A., Tuel-Ahlgren, L., Tuong, D., Pond, D., Luben, R., and Uckun, F. M. Electromagnetic field-induced stimulation of Bruton's tyrosine kinase (BTK). J. Biol. Chem., 273: 9119-9123, 1998.
39. Xiao, J., Messinger, Y., Jin, J., Myers, D. E., Bolen, J. B., and Uckun, F. M. Signal transduction through the β1 integrin family surface adhesion molecules VLA-4 and VLA-5 of human B-cell precursors activates CD19 receptor-associated protein-tyrosine kinases. J. Biol. Chem., 271: 7659-7664, 1996.
40. Kaplan, G. C., Pillion, D. J., Rutter, W. J., Kim, H., and Barker, P. E. Insulin receptor overexpression in a human pre-B acute lymphocytic leukemia cell line with a t(1;19) chromosome translocation near the INSR locus. Biochem. Biophys. Res. Commun., 159: 1275-1282, 1989.
41. Newman, J. D., Harrison, L. C., Eckardt, G. S., and Jack, I. Enhanced insulin-receptor tyrosine kinase activity associated with chromosomal translocation (1:19) in a pre-B-cell leukemia line. Int. J. Cancer, 50: 500-504, 1992.
42. Bushkin, I., and Zick, Y. Alterations in insulin receptor kinase activity during differentiation of HL-60 cells. Biochem. Biophys. Res. Commun., 172: 676-682, 1990.